Zealand Pharma A/S (OTCMKTS:ZLDPF) Given Market Perform Rating at William Blair

William Blair reissued their market perform rating on shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) in a research report report published on Friday morning, MarketBeat reports.

Several other equities analysts have also recently commented on ZLDPF. BTIG Research upgraded Zealand Pharma A/S to a “strong-buy” rating in a research note on Friday, November 28th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Zealand Pharma A/S in a report on Tuesday, December 16th. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of Zealand Pharma A/S in a research note on Friday. Four investment analysts have rated the stock with a Strong Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy”.

Zealand Pharma A/S Stock Down 30.7%

Shares of OTCMKTS ZLDPF traded down $17.72 during midday trading on Friday, reaching $39.95. 83,428 shares of the company’s stock were exchanged, compared to its average volume of 822. The company has a debt-to-equity ratio of 0.02, a quick ratio of 14.10 and a current ratio of 14.10. Zealand Pharma A/S has a 52-week low of $35.93 and a 52-week high of $101.29. The business’s fifty day moving average price is $64.22 and its two-hundred day moving average price is $70.62. The stock has a market capitalization of $2.84 billion, a PE ratio of 2.92 and a beta of 0.75.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last issued its quarterly earnings results on Thursday, February 19th. The company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($1.34) by $0.53. Zealand Pharma A/S had a return on equity of 49.76% and a net margin of 70.06%.The firm had revenue of $10.79 million during the quarter, compared to the consensus estimate of $19.69 million. Analysts forecast that Zealand Pharma A/S will post -2.19 EPS for the current year.

Trending Headlines about Zealand Pharma A/S

Here are the key news stories impacting Zealand Pharma A/S this week:

• Positive Sentiment: Roche and Zealand reported the midstage (Phase 2) trial met its prespecified goal and highlighted tolerability, saying the data support further development of petrelintide for chronic weight management (either alone or in combination). Roche, Zealand Pharma Obesity Drug Hits Goal in Midstage Trial
• Positive Sentiment: Zealand’s own releases and coverage from business outlets framed the Phase 2 readout as positive for petrelintide, emphasizing potential to advance the program and the drug’s amylin-analog mechanism as a differentiated approach in weight management. Zealand Pharma announces positive Phase 2 results for petrelintide
• Positive Sentiment: Industry press also described the Roche/Zealand collaboration as achieving a successful midstage readout, supporting continued development of the program. Roche succeeds in mid-stage trial for obesity drug developed with Zealand
• Neutral Sentiment: William Blair reaffirmed a “market perform” rating on Zealand, leaving guidance unchanged — a sign analysts are holding a wait?and?see stance rather than turning bullish. (Current quoted price cited in analyst notes: $39.95.)
• Neutral Sentiment: Cantor Fitzgerald likewise reaffirmed a “neutral” rating, indicating no immediate upgrades from these sell?side firms despite the trial news. (Current quoted price cited in analyst notes: $39.95.)
• Negative Sentiment: MarketWatch reported that the trial’s weight?loss results were disappointing relative to market expectations, and that focus on the magnitude of weight loss (rather than tolerability or hit/miss of a specific statistical endpoint) spurred the selloff. Disappointing weight-loss-trial results from Zealand Pharma sends shares tumbling
• Negative Sentiment: MSN summarized investor disappointment over the weight?loss magnitude in the Phase 2 readout and noted the sharp share decline as traders punished the perceived shortfall versus expectations. This Danish biotech’s new weight-loss drug disappointed investors, and its stock is tumbling

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark?based biopharmaceutical company specializing in the discovery, design and development of peptide?based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.